UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~January~~ 12March 13, 2026

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		001-39218		16-0977505
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

11311 Concept Blvd

Largo, FL

33773

(Address of principal executive offices)

(Zip code)

(727) 392-6464

(Registrant'’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		CNMD		NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0102 ~~Regulation~~Departure FDof ~~Disclosure~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 13, 2026, CONMED Corporation (the “Company”) ~~is furnishing as Exhibit~~announced ~~99.1~~that toAndrew ~~this~~Moller, ~~Current~~age ~~Report~~51, onwill ~~Form~~be ~~8-K~~appointed anInterim ~~investor~~Principal ~~presentation~~Financial ~~that~~Officer of the Company ~~will~~effective beMarch ~~presenting at the J.P. Morgan Healthcare Conference on January 12~~15, 2026. ~~The investor presentation includes preliminary 2026 financial guidance and is available on the CONMED Corporation website www.conmed.com in the Investors section under News & Events-Presentations.~~

~~The~~Mr. ~~information~~Moller ~~contained~~joined inthe ~~this~~Company ~~Current~~in ~~Report~~January on2025 ~~Form~~as ~~8-K~~Vice ~~(including~~President, ~~Exhibit~~Corporate ~~99.1)~~Controller isand ~~being~~was ~~furnished~~appointed ~~and~~as ~~shall~~the ~~not~~Company’s bePrincipal ~~deemed~~Accounting ~~“filed”~~Officer ~~for~~in ~~purposes~~April of2025. ~~Section~~Prior 18to ofjoining the Company, ~~Securities~~he ~~Exchange~~was ~~Act of~~employed ~~1934~~by Smith & Nephew from May 2019 to December 2024, where he most recently served as ~~amended~~Global ~~(the~~Controller and ~~“Exchange~~CFO ~~Act”)~~Asia-Pacific. Prior to those roles, orMr. ~~otherwise~~Moller ~~subject~~served toin ~~the~~a ~~liabilities~~variety of ~~that~~roles ~~section~~at orStanley ~~Sections~~Black & 11Decker ~~and~~from ~~12(a)(2) of~~2011 ~~the~~to ~~Securities~~2019, including ~~Act~~Director of ~~1933,~~Internal asAudit. ~~amended~~Mr. ~~(the~~Moller ~~“Securities~~is ~~Act”),~~a ~~and~~certified ~~shall~~public ~~not~~accountant, beand ~~deemed~~he ~~incorporated~~holds bya ~~reference~~Master ~~into~~of ~~any~~International Business ~~filing~~Studies ~~under~~from the ~~Securities~~University ~~Act~~of orSouth ~~the~~Carolina ~~Exchange~~and ~~Act,~~a ~~except~~Bachelor asof ~~shall~~Science bedegree ~~expressly~~in ~~provided~~Business byAdministration ~~specific~~from ~~reference~~the inCollege ~~such filing~~of Charleston.

There are no related-party transactions that would be required to be disclosed under Item 9404(a) of Regulation S-K with respect to Mr.01 ~~Financial~~Moller. ~~Statements~~There are no family relationships between Mr. Moller and the ~~Exhibits~~members of the Company’s Board of Directors. There was no change to Mr. Moller’s compensation arrangements in connection with his appointment as Interim Principal Financial Officer.

~~(d) Exhibits~~1

~~The following exhibit is included as part of this Current Report on Form 8-K:~~ Signature

Number		Description of Exhibits
99.1		CONMED Corporation Investor Presentation dated January 12, 2026.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Signature

Date: March 13, 2026	CONMED CORPORATION
	(Registrant)

	By:	/s/ Patrick J. Beyer
	Name:	Patrick J. Beyer
	Title:	President and Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

January 12, 2026

CONMED CORPORATION

(Registrant)

/s/ Todd W. Garner

Todd W. Garner

Executive Vice President, Finance and Chief Financial Officer

Filing Compare · CONMED Corp